# Rentokil Initial share price today (Rentokil Initial plc, RTO)

> Rentokil Initial plc's earnings have grown faster than its share price. Earnings per share grew +19.5% in a year while the price moved −15.3%. RTO · Industrials · Specialty Business Services · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/rto

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Slowing from a peak, from fewer quarters than usual
- Price: $23.57 (−15.3% in a year)
- P/E: 24.7×, over 3.8 years
- Revenue (Jun 2026): $3.6 B (+6.7% on a year ago)
- Profit (Jun 2026): $196 M (+4.3% on a year ago)
- Operating margin: 12.8% (+0.4 points on a year ago)
- ROE: 9%, FY25
- ROIC: 7.4%, against a 5.5% cost of capital: +1.9 points

The main question: yearly earnings per share moved +19.5% while the share price moved −15.3%. ## What is the Rentokil Initial share price today? Rentokil Initial plc's share price was $23.57 at the close on 3 November 2026. It has been moving sideways for 16 weeks. That is 16.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between $20 and $34, and at that close it sat 26% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 27 weeks running. Over the last 10 years the share price moved +81% while the S&P 500 moved +255%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 1 May 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Rentokil Initial pay? Rentokil Initial plc paid $0.25 per share over the last four reported quarters. The most recent declaration was $0.04 for Jun 2026. At today's price of $23.57 that is a yield of 1.06%, based on dividends already paid, not a forecast. ## Which stock lists is Rentokil Initial on? Rentokil Initial is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Rentokil Initial profitable? Rentokil Initial plc earned $196 M of net profit in the Jun 2026 quarter, +4.3% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was $470 M. Over 4 years profit has grown 7.2% a year on average. That is 5.5% of the quarter's revenue. The same quarter a year earlier earned $248 M. For the full year, FY25 profit was $470 M (+19.9% on the year before). Why profit moved: revenue changed +6.7% on a year earlier and the margin moved +0.4 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +8.4% and revenue +3.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Rentokil Initial make, and is it growing? Rentokil Initial plc reported $3.6 B of revenue in the Jun 2026 quarter, +6.7% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 4 years it has grown 14.6% a year on average. The last full year, FY25, came in at $6.9 B. FY25 revenue was $6.9 B, +4.4% on the year before. Recent pace: the last four quarters grew +3.2% on average, against 14.6% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +9.2%, against +30.0% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −6.1%, against +7.1% a year (rolling over). ## How much of every $100 of sales does Rentokil Initial keep? Rentokil Initial plc's operating margin was 12.8% in the Jun 2026 quarter, 0.4 percentage points higher than the same quarter a year ago. Over the last four quarters it has moved −0.3 percentage points. Across 6 years it has been between 11.4% and 13.4%. The latest quarter is within that range. Why the margin moved: operating margin changed −0.3 percentage points on the year while gross margin changed −0.1 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Rentokil Initial's profit turning into cash? Over the last 3 years, 206% of Rentokil Initial plc's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $972 M of operating cash against $470 M of profit. After $208 M of spending on assets, $764 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Rentokil Initial's cash go? Rentokil Initial plc does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $634 M on assets over the last 3 years. Averaged over those years that is 3.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $634 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Rentokil Initial's P/E ratio, and how does it compare with its own history? Rentokil Initial plc's P/E is 24.7×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +19.5% while the price moved −15.3%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved −4.8% a year; about −1.8% a year came from earnings growth and about −3.0 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Rentokil Initial business getting better or worse? Rentokil Initial plc's business is slowing from a peak. Revenue and profit growth have slowed sharply (revenue growth from +54.9% at its peak to +9.2% now), while ROCE is still 15.5%. This is based on 12 quarters of 3 measures, with some gaps. Why it matters: slowing from a peak is where good stories often end quietly. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Rentokil Initial earn on its capital? Rentokil Initial plc earned a ROE of 9% in FY25. That is up from a low of 6% in FY22. Its return on capital used (ROIC) is 1.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 6.8% net margin and 0.48× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 6.8% net margin × 0.48× asset turnover × 2.63× leverage (assets divided by equity) ≈ 8.6% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 7.4% − 5.5% = +1.9 percentage points. The 5.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Rentokil Initial have too much debt? Rentokil Initial plc has total debt of $6.1 B against shareholder equity of $5.5 B as of Jun 2026, so its debt is 1.11× its equity. Year by year, that ratio went from 1.56 in FY21 to 1.12 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Rentokil Initial shareholding pattern? We have no ownership or short-position figures for Rentokil Initial plc, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 1.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Rentokil Initial from balance-sheet trouble? For Rentokil Initial plc, the Z-score is 2.29. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.29 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Rentokil Initial rank in its industry? 46.7 out of 100, rank 16 of 30 in Specialty Business Services, with 51% of the evidence available. Rentokil Initial plc scores 46.7 out of 100 against the 30 companies it is compared with in Specialty Business Services, ranking 16. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 18.8 + 13.2 + 9.6 + 5.1 = 46.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Rentokil Initial compared with? Rentokil Initial ranks 16 of 30 Specialty Business Services companies on the 4-Factor Sector Score, with 46.7 out of 100. 1. [Cintas Corporation](https://www.sectoralpha.in/us/stocks/ctas) CTAS · leader · Most evidence points up · 85% evidence 68.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Revenue 9.5% · Profit 11.3% · Operating margin change 1.4 points · 95% evidence Capital efficiency 21.0/25 · ROCE 34.3% · Operating margin 24.1% · 76% evidence Valuation 6.1/20 · P/E 39.3× · PEG 3.17 · 65% evidence Relative strength 17.3/20 · Lead over its industry 3.9% · Lead over S&P 500 11.8% · 1 year 20.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 23.9 + 21 + 6.1 + 17.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [UL Solutions Inc.](https://www.sectoralpha.in/us/stocks/uls) ULS · turning · Most evidence points up · 81% evidence 66.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 6.6% · Profit 54.4% · Operating margin change 0.7 points · 83% evidence Capital efficiency 20.5/25 · ROCE 26.4% · Operating margin 18.4% · 76% evidence Valuation 13.0/20 · P/E 40.7× · PEG 0.77 · 65% evidence Relative strength 8.1/20 · Lead over its industry -13.8% · Lead over S&P 500 -7.3% · 1 year -6.1% · 100% evidence · 1 of 12 weeks ahead Exact sum: 25 + 20.5 + 13 + 8.1 = 66.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [RELX PLC](https://www.sectoralpha.in/us/stocks/relx) RELX · breaking out · Too little evidence to rank firmly · 51% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue n/a · Profit n/a · Operating margin change 1.1 points · 26% evidence Capital efficiency 21.6/25 · ROCE 36.1% · Operating margin 32% · 76% evidence Valuation 10.4/20 · P/E 18.3× · PEG n/a · 15% evidence Relative strength 13.9/20 · Lead over its industry -2.9% · Lead over S&P 500 4.6% · 1 year -6.8% · 100% evidence · 8 of 12 weeks ahead Exact sum: 19.8 + 21.6 + 10.4 + 13.9 = 65.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 4. [ABM Industries Incorporated](https://www.sectoralpha.in/us/stocks/abm) ABM · leader · Evidence leans up · 85% evidence 63.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.5/35 · Revenue 6% · Profit 44% · Operating margin change 0.5 points · 95% evidence Capital efficiency 10.2/25 · ROCE 8.3% · Operating margin 4.3% · 76% evidence Valuation 15.5/20 · P/E 16.9× · PEG 0.33 · 65% evidence Relative strength 17.8/20 · Lead over its industry 6.1% · Lead over S&P 500 14.1% · 1 year 27.8% · 100% evidence · 9 of 12 weeks ahead Exact sum: 19.5 + 10.2 + 15.5 + 17.8 = 63 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Cass Information Systems, Inc.](https://www.sectoralpha.in/us/stocks/cass) CASS · quiet · Evidence leans up · 85% evidence 60.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.5/35 · Revenue 6.4% · Profit 21.9% · Operating margin change 0.5 points · 95% evidence Capital efficiency 13.1/25 · ROCE 7.1% · Operating margin 29.7% · 76% evidence Valuation 14.8/20 · P/E 17.9× · PEG 0.72 · 65% evidence Relative strength 10.5/20 · Lead over its industry -1.4% · Lead over S&P 500 5.8% · 1 year 36% · 100% evidence · 5 of 12 weeks ahead Exact sum: 22.5 + 13.1 + 14.8 + 10.5 = 60.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Maximus, Inc.](https://www.sectoralpha.in/us/stocks/mms) MMS · breaking out · Evidence leans up · 81% evidence 57.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.1/35 · Revenue -3.3% · Profit 17% · Operating margin change 0.3 points · 83% evidence Capital efficiency 15.8/25 · ROCE 14.6% · Operating margin 12.6% · 76% evidence Valuation 16.2/20 · P/E 7.6× · PEG 0.31 · 65% evidence Relative strength 8.4/20 · Lead over its industry -16.7% · Lead over S&P 500 -10% · 1 year -22.1% · 100% evidence · 1 of 12 weeks ahead Exact sum: 17.1 + 15.8 + 16.2 + 8.4 = 57.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [CBIZ, Inc.](https://www.sectoralpha.in/us/stocks/cbz) CBZ · Evidence leans up · 65% evidence 57.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.6/43.75 · Revenue 3.8% · Profit 34.6% · Operating margin change 2 points · 95% evidence Capital efficiency 13.5/31.25 · ROCE 7.7% · Operating margin 13.3% · 76% evidence Valuation 18.4/25 · P/E 20.7× · PEG 0.4 · 65% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 25.6 + 13.5 + 18.4 = 57.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Thomson Reuters Corporation](https://www.sectoralpha.in/us/stocks/tri) TRI · breaking out · Evidence leans up · 81% evidence 56.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 7% · Profit 1.6% · Operating margin change 4.2 points · 83% evidence Capital efficiency 17.0/25 · ROCE 15.7% · Operating margin 28.3% · 76% evidence Valuation 5.5/20 · P/E 21.5× · PEG 6.29 · 65% evidence Relative strength 12.2/20 · Lead over its industry -6.9% · Lead over S&P 500 0.5% · 1 year -21.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 17 + 5.5 + 12.2 = 56.1 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 9. [First Advantage Corporation](https://www.sectoralpha.in/us/stocks/fa) FA · quiet · Evidence leans up · 74% evidence 53.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.6/35 · Revenue 32.8% · Profit n/a · Operating margin change 2.6 points · 62% evidence Capital efficiency 9.2/25 · ROCE 4.9% · Operating margin 12.8% · 76% evidence Valuation 4.3/20 · P/E 123.1× · PEG 4.11 · 65% evidence Relative strength 14.7/20 · Lead over its industry 21.2% · Lead over S&P 500 29.7% · 1 year 63.9% · 100% evidence · 7 of 12 weeks ahead Exact sum: 25.6 + 9.2 + 4.3 + 14.7 = 53.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [LegalZoom.com, Inc.](https://www.sectoralpha.in/us/stocks/lz) LZ · turning · Evidence leans up · 74% evidence 53.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.8/35 · Revenue 12% · Profit -41.4% · Operating margin change 7 points · 62% evidence Capital efficiency 15.9/25 · ROCE 23.1% · Operating margin 5.4% · 76% evidence Valuation 3.9/20 · P/E 62.4× · PEG 9.26 · 65% evidence Relative strength 8.5/20 · Lead over its industry -17.4% · Lead over S&P 500 -10.7% · 1 year -33.8% · 100% evidence · 2 of 12 weeks ahead Exact sum: 24.8 + 15.9 + 3.9 + 8.5 = 53.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Global Payments Inc.](https://www.sectoralpha.in/us/stocks/gpn) GPN · turning · Evidence leans up · 71% evidence 52.7 out of 100 Growth Capital Valuation Relative
12. [Aramark](https://www.sectoralpha.in/us/stocks/armk) ARMK · turning · Evidence leans up · 64% evidence 52.0 out of 100 Growth Capital Valuation Relative
13. [TIC Solutions, Inc.](https://www.sectoralpha.in/us/stocks/tic) TIC · breaking out · Evidence leans down · 61% evidence 49.0 out of 100 Growth Capital Valuation Relative
14. [Eastman Kodak Company](https://www.sectoralpha.in/us/stocks/kodk) KODK · quiet · Evidence leans down · 64% evidence 47.8 out of 100 Growth Capital Valuation Relative
15. [Dolby Laboratories, Inc.](https://www.sectoralpha.in/us/stocks/dlb) DLB · losing its lead · Evidence leans down · 81% evidence 47.0 out of 100 Growth Capital Valuation Relative
16. Rentokil Initial plc this page RTO · basing · Too little evidence to rank firmly · 51% evidence 46.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue n/a · Profit n/a · Operating margin change 0.4 points · 26% evidence Capital efficiency 13.2/25 · ROCE 8.6% · Operating margin 12.8% · 76% evidence Valuation 9.6/20 · P/E 29.8× · PEG n/a · 15% evidence Relative strength 5.1/20 · Lead over its industry -27% · Lead over S&P 500 -21.4% · 1 year -13% · 100% evidence · 0 of 12 weeks ahead Exact sum: 18.8 + 13.2 + 9.6 + 5.1 = 46.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 17. [Transcat, Inc.](https://www.sectoralpha.in/us/stocks/trns) TRNS · quiet · Evidence leans down · 81% evidence 45.3 out of 100 Growth Capital Valuation Relative
18. [AZZ Inc.](https://www.sectoralpha.in/us/stocks/azz) AZZ · quiet · Evidence leans down · 85% evidence 45.0 out of 100 Growth Capital Valuation Relative
19. [Copart, Inc.](https://www.sectoralpha.in/us/stocks/cprt) CPRT · turning · Evidence leans down · 85% evidence 43.3 out of 100 Growth Capital Valuation Relative
20. [RB Global, Inc.](https://www.sectoralpha.in/us/stocks/rba) RBA · turning · Evidence leans down · 81% evidence 42.8 out of 100 Growth Capital Valuation Relative
21. [Target Hospitality Corp.](https://www.sectoralpha.in/us/stocks/th) TH · quiet · Evidence leans down · 64% evidence 42.2 out of 100 Growth Capital Valuation Relative
22. [Amentum Holdings, Inc.](https://www.sectoralpha.in/us/stocks/amtm) AMTM · basing · Evidence leans down · 64% evidence 40.7 out of 100 Growth Capital Valuation Relative
23. [Quad/Graphics, Inc.](https://www.sectoralpha.in/us/stocks/quad) QUAD · losing its lead · Evidence leans down · 64% evidence 40.4 out of 100 Growth Capital Valuation Relative
24. [Cimpress plc](https://www.sectoralpha.in/us/stocks/cmpr) CMPR · quiet · Evidence leans down · 64% evidence 36.7 out of 100 Growth Capital Valuation Relative
25. [BlackSky Technology Inc.](https://www.sectoralpha.in/us/stocks/bksy) BKSY · quiet · Evidence leans down · 64% evidence 36.6 out of 100 Growth Capital Valuation Relative
26. [UniFirst Corporation](https://www.sectoralpha.in/us/stocks/unf) UNF · quiet · Evidence leans down · 85% evidence 36.4 out of 100 Growth Capital Valuation Relative
27. [Resolute Holdings Management, Inc.](https://www.sectoralpha.in/us/stocks/rhld) RHLD · basing · Most evidence points down · 64% evidence 31.9 out of 100 Growth Capital Valuation Relative
28. [BrightView Holdings, Inc.](https://www.sectoralpha.in/us/stocks/bv) BV · turning · Most evidence points down · 71% evidence 30.4 out of 100 Growth Capital Valuation Relative
29. [Spire Global, Inc.](https://www.sectoralpha.in/us/stocks/spir) SPIR · quiet · Most evidence points down · 71% evidence 23.5 out of 100 Growth Capital Valuation Relative
30. [BUUU Group Limited](https://www.sectoralpha.in/us/stocks/buuu) BUUU · leader · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Specialty Business Services](https://www.sectoralpha.in/us/sectors/specialty-business-services), all 30 compared on one page. ## Which companies are close to Rentokil Initial in size? Rentokil Initial is the 9th largest of 31 Specialty Business Services companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: RB Global, Inc., UL Solutions Inc. and Aramark. Just below it: Dolby Laboratories, Inc., Amentum Holdings, Inc. and UniFirst Corporation. ### Specialty Business Services companies close in size

1. [RB Global, Inc.](https://www.sectoralpha.in/us/stocks/rba) $17.3 billion
2. [UL Solutions Inc.](https://www.sectoralpha.in/us/stocks/uls) $16.2 billion
3. [Aramark](https://www.sectoralpha.in/us/stocks/armk) $14.4 billion
4. Rentokil Initial plc $12 billion
5. [Dolby Laboratories, Inc.](https://www.sectoralpha.in/us/stocks/dlb) $5.9 billion
6. [Amentum Holdings, Inc.](https://www.sectoralpha.in/us/stocks/amtm) $5.5 billion
7. [UniFirst Corporation](https://www.sectoralpha.in/us/stocks/unf) $4.6 billion

[All 31 Specialty Business Services companies, largest first](https://www.sectoralpha.in/us/sectors/specialty-business-services#all-companies)

### Companies close in size in other industries

1. [Lennox International Inc.](https://www.sectoralpha.in/us/stocks/lii) $12.1 billion · Building Products & Equipment
2. [IonQ, Inc.](https://www.sectoralpha.in/us/stocks/ionq) $12.1 billion · Computer Hardware
3. Rentokil Initial plc $12.1 billion
4. [Elanco Animal Health Incorporated](https://www.sectoralpha.in/us/stocks/elan) $12 billion · Drug Manufacturers - Specialty & Generic
5. [SK Telecom Co., Ltd.](https://www.sectoralpha.in/us/stocks/skm) $12 billion · Telecom Services

## What else do people ask about Rentokil Initial? ### What is Rentokil Initial's stock price today? Rentokil Initial plc's stock price is $23.57, −15.3% over the past year. The whole company is worth $12.0 B on the market. In the last 52 weeks it traded between $20 to $34; today it is 26% of the way up from the low, 16.8% below its 200-day average (as of 3 November 2026). ### What were Rentokil Initial's latest quarterly results? Rentokil Initial plc reported revenue of $3.6 B and net profit of $196 M for the Jun 2026 quarter. Revenue rose 6.7% and profit rose 4.3% compared with a year earlier. Earnings per share were $0.08. The operating margin was 12.8%, 0.4 percentage points higher than a year earlier (as of 3 November 2026). ### What is Rentokil Initial's market cap? Rentokil Initial plc's market capitalisation is $12.0 B at a stock price of $23.57. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Rentokil Initial performing? Rentokil Initial plc's share price has been moving sideways for 16 weeks. In its latest quarter, revenue rose 6.7% and profit rose 4.3% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 27 weeks running (as of 3 November 2026). ### Will Rentokil Initial's stock price go up? This page does not forecast Rentokil Initial plc's stock price. What it shows instead: the stock price is $23.57, and it has been moving sideways for 16 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Rentokil Initial in its business cycle? Rentokil Initial plc's FY25 operating margin was 12.7%, against a 6-year range of 11.4% to 13.4%: the middle of its own range, neither a peak nor a low. The latest quarter was 12.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Rentokil Initial story? The main question: yearly earnings per share moved +19.5% while the share price moved −15.3%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Rentokil Initial a stock worth studying right now? What the numbers show: Rentokil Initial plc's earnings have grown faster than its share price. Earnings per share grew +19.5% in a year while the price moved −15.3%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.